Matthew Herper on Muck Rack

Matthew Herper Verified

New York
Senior Editor — Forbes
As seen in:  Forbes

Forbes reporter covering science and medicine

Obama's Precision Medicine Initiative Is A Great Idea

forbes.com — This morning, President Obama is going to announce the new "Precision Medicine Initiative that he teased in his State of the Union address on January 20 to a roomful of luminaries including the research heads of several major drug makers. It's a gimmicky grab for budget money that's scant on [...]

Nothing. Is It What Medicine's Missing?

forbes.com — Michael Specter of the New Yorker has a great profile of Harvard University's Ted Kaptchuk. It's a lot of what I was trying to get at here, and here.

Moving Mobile Health Past The Hype

forbes.com — Imagine if the iPod could only play Frank Sinatra songs, or if the latest iPhone version was a not-so-smart-phone with just text, email and a weather app. It's not just the existence of mobile computers we call smart phones that has changed our lives in profound ways, but the content delivered by them.

This Giant Drug Firm Won't Invent Medicines. Investors Are Cheering

forbes.com — In early January Brenton "Brent" Saunders, the chief executive of upstart pharmaceutical giant Actavis , reclined in a medical chair on a stage in an Orlando hotel ballroom as a plastic surgeon pierced his face 30 times, delivering needles full of Botox to the crooks of his eyes and nose and injecting Juvederm Voluma, a dermal filler, into his cheeks.

We Need A Clinical Data Revolution in Healthcare: A Lesson From South Korea

forbes.com — Despite incredible advances in science and technology over the last decade, modern drug development remains a complex and costly process. Only about 7% of early-stage drugs make it to market, with development costs averaging $2.6 billion, according to the Tufts Center for the Study of Drug Development. When you weigh [...]

Lawsuit Says Billionaire's Health Venture Is 'Fraudulent' And Could Harm Patients

forbes.com — On the television newsmagazine "60 Minutes" and in a cover story for Forbes, Patrick Soon-Shiong, the world's richest doctor, has promised that his new company, NantHealth, can dramatically improve care for cancer patients everywhere. "I'm incredibly encouraged to say that we are on the path," Soon-Shiong told 60 Minutes' Sanjay Gupta.

Roche Spends $1.03 Billion For Majority Stake In Foundation Medicine

forbes.com — Roche, the world's largest maker of cancer drugs, is spending $1.03 billion to buy a 56.3% stake in Cambridge, Mass.-based Foundation Medicine, a company that uses genetics to help select drugs for cancer patients. Roche, based in Basel, Switzerland, will also market Foundation's diagnostic tests outside the U.S., help educate [...]

Drug Data Dump: Pfizer, Biogen, AbbVie

forbes.com — Three big-cap drug companies dropped news today, likely to give investors time to digest it before next week's big J.P. Morgan investor meeting in San Francisco. Quick thoughts on each. 1. Biogen Idec announced mixed results of its most important experimental drug, anti-LINGO, in acute optic neuritis, or nerve damage in [...]

Surprise! With $60 Million Genentech Deal, 23andMe Has A Business Plan

forbes.com — This is more like it. A deal being announced today with Genentech points the way for 23andMe, the personal genetics company backed by Facebook billionaire Yuri Milner and Google Ventures, to become a sustainable business - even if the company's discussions with the U.S. Food and Drug Administration stretch on for [...]

Moderna Therapeutics Raises $450 Million In Biggest Biotech Private Round Ever

forbes.com — Moderna Therapeutics, a biotechnology company in Cambridge, Mass., is announcing today that it has raised $450 million from investors including Viking Global Investors LP, Invus, RA Capital Management, and Wellington Management Company, LLP, AstraZeneca and Alexion Pharmaceuticals. That appears to be is the largest private fundraising round for any biotechnology company, [...]
More Articles →
Jan 30, 2015

@aaronquinlan They're just creating the cohort, hoping the sequencing money will come later, or from other projects, or price comes down.

Jan 30, 2015

RT @meghanor: e.g. women getting less pain meds than men, told there is nothing wrong w/ them when something is, etc. Better data and tools will help.

Jan 30, 2015

RT @meghanor: all for precision medicine,but initiative shd encompass awareness of the unconscious bias that leads doctors to be imprecise.

Jan 30, 2015

$ABBV's stock today is a blow to $ESRX's battle against drug prices. If discounting doesn't get you share price, why do it?

Jan 30, 2015

. @kennamshaw @dgmacarthur It's still vague. But it's a good idea -- much more clear cut than BRAIN. We need to do this.

Jan 30, 2015

Fun thought. $VRX is spending more on $DNDNQ than it will spend on R&D in 2015.

Jan 30, 2015

RT @forbeshealth: Why too many clinical trials fail -- and a solution that could increase returns on pharma R&D: onforb.es/15Vtfe7 by …

Jan 30, 2015

Now investors will value the Dendreon assets at twice what they were, because $VRX. (Sarcastic, half joking.)

Jan 30, 2015

You need to cut back, dude. RT @adamfeuerstein I had this crazy dream that $VRX bought $DNDN…. I must be drunk.

Learn how to connect with Matthew on social media by joining Muck Rack Pro



Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.


Share This Profile